ArticleMolecular neurobiology2025
Neuroprotective and Cognitive Benefits of a Ketogenic Diet in a Type 2 Diabetes Rat Model.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ketogenic metabolic therapy: low-carbohydrate interventions as novel neuroprotective strategies for cognitive dysfunction in diabetes.Frontiers in aging neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a widespread metabolic disease that also increases the risk of cognitive decline through mechanisms such as oxidative stress, inflammation, and vascular damage. Recently, the ketogenic diet has attracted attention as a nutritional approach that may improve glucose control and support cognitive health in diabetes. The present study evaluated the neuroprotective and behavioral effects of a ketogenic diet (KD) in a rat model of type 2 diabetes mellitus (T2DM). Adult male Wistar rats were assigned to four groups (n = 7 each): control (normal diet), KD, diabetic (high-fat diet + nicotinamide (60 mg/kg, ip) / streptozotocin (50 mg/kg, i.p)), and diabetic + KD. After eight weeks, we assessed anxiety-like and memory behaviors via the hole-board, elevated plus maze, and object recognition tests. Oxidative stress markers (malondialdehyde, MDA; glutathione, GSH) and neuroinflammatory mediators (S100β, TNF-α, IL-6) were quantified. Histopathological and immunohistochemical analyses of CA1, CA3, and dentate gyrus regions evaluated neuronal integrity and oxidative DNA damage (8-OHdG) and neurotrophic factor BDNF. KD alone induced ketosis and modest anxiety-like behaviors but preserved recognition memory. In diabetic rats, KD significantly reduced hyperglycemia and insulin (p < 0.001-0.01), ameliorated oxidative damage (p < 0.01), and partially normalized S100β, TNF-α, IL-6, and BDNF levels (p < 0.05). Behaviorally, KD attenuated diabetes-induced anxiety and improved cognitive difference score (p < 0.05). Histologically, KD mitigated diabetes-associated neuronal degeneration and reduced 8-OHdG immunopositivity. These findings indicate that KD confers neuroprotective benefits under diabetic conditions by modulating glycemic control, oxidative stress, inflammation, and neurotrophic support in the brain.
Indexed as
Identifiers
41317286What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.